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PVascular Effects of Nicotinic Acid
Effects of High-Dose Modified-Release
Nicotinic Acid on Atherosclerosis and
Vascular Function
A Randomized, Placebo-Controlled, Magnetic Resonance Imaging Study
Justin M. S. Lee, MB, BCH,* Matthew D. Robson, PHD,* Ly-Mee Yu, MSC,†
Cheerag C. Shirodaria, MD,* Colin Cunnington, MBBS,* Ilias Kylintireas, MD,*
Janet E. Digby, PHD,* Thomas Bannister, BA,* Ashok Handa, MB, BS,‡ Frank Wiesmann, MD,*
Paul N. Durrington, MD,§ Keith M. Channon, MD,* Stefan Neubauer, MD,*
Robin P. Choudhury, DM*
Oxford and Manchester, United Kingdom
Objectives Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and
measures of vascular function.
Background NA raises high-density lipoprotein cholesterol (HDL-C) and reduces low-density lipoprotein cholesterol and is
widely used as an adjunct to statin therapy in patients with coronary artery disease. Although changes in plasma
lipoproteins suggest potential benefit, there is limited evidence of the effects of NA on disease progression when
added to contemporary statin treatment.
Methods We performed a double-blind, randomized, placebo-controlled study of 2 g daily modified-release NA added to
statin therapy in 71 patients with low HDL-C (40 mg/dl) and either: 1) type 2 diabetes with coronary heart dis-
ease; or 2) carotid/peripheral atherosclerosis. The primary end point was the change in carotid artery wall area,
quantified by magnetic resonance imaging, after 1 year.
Results NA increased HDL-C by 23% and decreased low-density lipoprotein cholesterol by 19%. At 12 months, NA signifi-
cantly reduced carotid wall area compared with placebo (adjusted treatment difference: 1.64 mm2 [95% confi-
dence interval: 3.12 to 0.16]; p  0.03). Mean change in carotid wall area was 1.1  2.6 mm2 for NA ver-
sus 1.2  3.0 mm2 for placebo. In both the treatment and placebo groups, larger plaques were more prone to
changes in size (r  0.4, p  0.04 for placebo, and r  0.5, p  0.02 for NA).
Conclusions In statin-treated patients with low HDL-C, high-dose modified-release NA, compared with placebo, significantly
reduces carotid atherosclerosis within 12 months. (Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis
and Endothelial Function; NCT00232531) (J Am Coll Cardiol 2009;54:1787–94) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.036p
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rtherosclerosis is a systemic condition in which coronary,
arotid, and peripheral arterial disease frequently coexist (1). In
rom the *Department of Cardiovascular Medicine, University of Oxford and Oxford
entre for Clinical Magnetic Resonance Research (OCMR), Oxford, United
ingdom; †Centre for Statistics in Medicine and ‡Nuffield Department of Surgery,
niversity of Oxford, Oxford, United Kingdom; and the §Cardiovascular Research
roup, University of Manchester, Manchester, United Kingdom. This was an
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Manuscript received February 3, 2009; revised manuscript received May 26, 2009,
ccepted June 18, 2009.atients with atherosclerotic disease, low-density lipoprotein
holesterol (LDL-C) reduction with 3-hydroxy-3-methyl-
lutaryl-coenzyme A reductase inhibitors (“statins”) has con-
istently shown reduction in major cardiovascular events and
ortality (2–4). However, treatment of LDL-C with statins
See page 1795
revents only a minority of cardiovascular events. Epidemio-
ogical studies indicate a strong inverse relationship between-
oronary heart disease risk and high-density lipoprotein cho-
esterol (HDL-C) at all levels of LDL-C (5–7). This
elationship persists in patients who have been treated with
tatins, providing a rationale for additionally targeting low
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MRI of Atherosclerosis Response to Nicotinic Acid November 3, 2009:1787–94HDL-C (3). Nicotinic acid (NA)
raises HDL-C by approximately
20% to 25% and is the most effec-
tive clinically available drug for
HDL-C elevation (8,9).
Magnetic resonance imaging
(MRI) is a highly reproducible
technique that allows the accurate
quantification and characterization
of plaque, and for changes in re-
sponse to treatment to be identi-
fied in relatively small numbers of
patients (10–14). In addition,
MRI can assess central and pe-
ripheral arterial function in a single
ntegrated examination (13,15).
This study was designed to investigate the effects of
odified-release NA 2 g daily versus placebo on the progres-
ion of atherosclerosis, and vascular function, determined by
RI, in patients with pre-existing atherosclerosis and low
DL-C (40 mg/dl) in whom LDL-C was treated to
ontemporary targets with statins (16).
ethods
tudy background and population. This was an investigator-
nitiated, single-center, randomized, double-blind, placebo-
ontrolled study examining the effect of modified release
A, 2 g daily, (Niaspan, Merck KGaA, Darmstadt, Ger-
any). The study protocol was approved by the local
esearch ethics committee. Study reporting follows princi-
les recommended by the revised CONSORT statement
17). All patients provided written informed consent. Inclu-
ion criteria were: 1) HDL-C40 mg/dl in the previous 12
onths together with either: 2a) carotid atherosclerosis
30% to 70% stenosis identified using carotid ultrasound);
b) peripheral arterial disease (ankle-brachial pressure index
0.9); or 2c) type 2 diabetes with coronary artery disease
50% stenosis of major epicardial vessel at angiography).
here was no specific LDL-C inclusion criterion, but all
atients were already taking statins, the dosage of which was
etermined by their own physician. Exclusion criteria were
tandard contraindications to MRI or to NA (e.g., elevated
iver enzymes or known intolerance); severe carotid stenosis
70%); existing treatment with fibrates, nicorandil, or oral
itrates; recent acute coronary syndrome; uncontrolled dia-
etes; fasting triglyceride level 500 mg/dl; active peptic
lcer disease; and cardiac failure requiring diuretic treat-
ent. A computer generated randomization sequence was
erformed by Merck KGaA to generate study numbers in a
atio of 1:1, NA to placebo. Study medication was supplied
y Merck KGaA in the form of NA tablets and identical
lacebo tablets. Patients were randomized to NA or placebo
or 1 year. In keeping with clinical dosing regimens, NA (or
lacebo) was increased on a weekly basis from 375 mg to
Abbreviations
and Acronyms
CI  confidence interval
CRP  C-reactive protein
HDL-C  high-density
lipoprotein cholesterol
IMT  intima-media
thickness
LDL-C  low-density
lipoprotein cholesterol
MRI  magnetic resonance
imaging
NA  nicotinic acid00 mg, and then to 750 mg daily. Patients subsequently beceived 1,000 mg for 4 weeks, 1,500 mg for a further 4
eeks, and then 2,000 mg daily for the remainder of the
tudy. Participants were advised to take study medication at
ight, together with aspirin, if taking this already, to reduce
otential for flushing. MRI scans were performed at base-
ine, 6 months, and 12 months, and fasting blood samples
ere obtained before each scan. Further visits were sched-
led after 7 and 15 weeks for safety review. Medication
ompliance was determined by pill counts. The primary end
oint was absolute change in carotid artery wall area at 12
onths. Further pre-specified MRI end points were:
hange in aortic wall area, aortic distensibility, and brachial
rtery reactivity (flow-mediated dilation after forearm cuff
cclusion and response to sublingual glyceryl trinitrate).
RI. The MRI protocols (including sequence parameters)
sed in this study have been described in detail previously
13,15). To summarize, scans were performed on a 1.5-T
RI system (Sonata, Siemens, Erlangen, Germany) using a
ombination of surface and spine coils. Blood pressure was
onitored during the MRI study using a cuff on the left
rm. Electrocardiogram-gated turbo spin echo images with
lood and fat suppression were acquired to yield between 9
nd 11 axial images of the aorta (5-mm slice thickness and
-mm interslice gap) and carotid arteries (3-mm slice
hickness and no interslice gap). Images of the aorta were
btained from the level of the right pulmonary artery down-
ards. For the carotid arteries, the caudal most point of the
ifurcation was used to define the region covering the distal 2
m of the common carotid artery and the carotid bulb.
istensibility was assessed in the ascending and descending
orta at the level of the right pulmonary artery and at a level 11
m below this in the descending aorta—calculated by the
aximum relative change in cross-sectional area divided by the
ulse pressure. Brachial artery endothelial function (flow-
ediated dilation) was assessed by the maximum percent
hange in cross-sectional area after 5 min forearm ischemia.
ndothelium independent response to 400 m sublingual
lyceryl trinitrate was also determined.
mage analysis. Semiautomated edge detection algorithms
ased in Matlab (Mathworks Inc., Natick, Massachusetts)
ere used to contour vessel boundaries to determine wall
reas, as previously described (18). All images were analyzed
y a single experienced observer (J.L.) blinded to patient
dentity, scan time point, and treatment allocation. Intraob-
erver variation was determined by repeat analysis of 6
andomly selected patients yielding coefficients of variation
f 3% for carotid wall area and 2% for aortic wall area. For
uality control, a second blinded observer (T.B.) repeated
nalyses in 10 randomly selected patients. Interobserver
J.L. and T.B.) coefficient of variation was 5% for the
arotid and 2% for the aorta. Carotid wall area was ex-
ressed as the mean of all images including and below the
arotid bulb. Aortic wall area was expressed as the mean of
ll images from the level of the right pulmonary artery.
erum assays. Fasting blood samples were obtained at
aseline, 6 months, and 12 months. For safety monitoring,
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MRI  magnetic resonance imaging; NA  nicotinic acid; SBP  systolic blood pressure.
1789JACC Vol. 54, No. 19, 2009 Lee et al.
November 3, 2009:1787–94 MRI of Atherosclerosis Response to Nicotinic Acidiver enzymes (aspartate aminotransferase) and creatine
inase were measured at each time point and also during
p-titration of medication at 7 and 15 weeks. If significantly
levated, they were repeated after 2 weeks. Further plasma
nd serum samples were stored at 80°C pending batch
nalyses. Total cholesterol, HDL-C, and triglycerides were
easured, and LDL-C was calculated using the Friedwald
quation. Apolipoprotein AI, apolipoprotein B, and li-
oprotein(a) were assayed using immunoturbidimetric
ethods (ABX Diagnostics, Horiba ABX, Montpellier,
rance). C-reactive protein (CRP) and adiponectin were
etermined by Luminex multiplex bead assay using Milli-
lex MAP kits on a Bio-Plex system (Bio-Rad, Hercules,
alifornia).
tatistical analysis. Sample size was estimated from our
RI-based measurements (subsequently reported [13]) of
laque change in statin-treated patients. A minimum of 26
atients per group was required to detect a mean difference
SD) in the change in vessel wall area of 7.9 (10.3) mm2
power  0.8, alpha  0.05). Allowing for a 20% patient
rop-out rate (e.g., due to side-effects of study medication or
laustrophobia in magnetic resonance scanner), we planned to
ecruit 70 patients to retain a total sample size of 56. We
arried out an intention-to-treat analysis. Patients with at least
follow-up measure were included in the analysis. Our
rimary analysis was a mixed-effect model of the primary
utcome, with adjustment of side (within subject), time
within side), corresponding baseline measures, and baseline
rognostic covariates such as peripheral vascular disease, dia-
etes, HDL-C, total cholesterol, glucose, and blood pressure.Figure 1 Patient Flow Through the Trial
MRI  magnetic resonance imaging.aseline Characteristics ofti nts W o Completed First MRI ScanTable 1 B seline Characteristics ofPatients Who Completed First MRI Scan
NA Placebo
Men 31 (94%) 32 (94%)
Age (yrs) 65 9 65 9
Diabetes mellitus 21 (64%) 22 (65%)
Hypertension 28 (85%) 24 (71%)
History of smoking 30 (91%) 26 (76%)
Peripheral vascular disease 14 (42%) 10 (29%)
Previous myocardial infarction 17 (53%) 15 (44%)
Previous stroke 3 (9%) 6 (18%)
Previous coronary angioplasty 15 (45%) 14 (41%)
Previous coronary bypass grafting 11 (33%) 10 (29%)
Medications
ACE inhibitor 25 (76%) 24 (71%)
Beta-blocker 22 (67%) 21 (62%)
Aspirin 31 (94%) 30 (88%)
Clopidogrel 14 (42%) 9 (26%)
Statin (mean dose, mg) 33 (100%) 34 (100%)
Simvastatin 20 (35) 24 (36)
Atorvastatin 12 (24) 10 (23)
Rosuvastatin 1 (40) 0 (0)
Oral hypoglycemic agents 16 (48%) 15 (44%)
Insulin 11 (33%) 6 (18%)
BMI (kg/m2) 31 5 30 5
SBP (mm Hg) 132 15 141 22
DBP (mm Hg) 75 8 76 10
Heart rate (beats/min) 63 10 60 10
CE  angiotensin-converting enzyme; BMI  body mass index; DBP  diastolic blood pressure;
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MRI of Atherosclerosis Response to Nicotinic Acid November 3, 2009:1787–94similar approach was used for the other secondary outcomes.
alues are reported as mean  SD or median (interquartile
ange) if they are skewed data. Data were log-transformed to
eet the normal distribution assumption where stated. Pear-
on’s method was used to assess correlation. Statistical signif-
cance was assigned at a value of p 0.05. Only the statistician
as aware of the treatment allocation when performing the
nal analysis, and it was unblinded to the investigators after
he analysis. All statistical methods used in the analysis and
hoice of covariates for adjustments were determined before
lood Markers*Table 2 Blood Markers*
Baseline 6 Months 12 Months
Total-C (mg/dl)
NA 153 32 141 25 147 26
Placebo 161 42 159 35 154 25
p value† 0.003 0.06
HDL-C (mg/dl)
NA 39 6 46 9 48 7
Placebo 37 5 36 6 38 6
p value† 0.001 0.001
LDL-C (mg/dl)
NA 85 23 64 16 69 21
Placebo 84 32 80 28 80 22
p value† 0.002 0.01
Triglycerides (mg/dl)
NA 168 (134–206) 150 (91–190) 150 (94–180)
Placebo 192 (132–248) 182 (144–248) 181 (143–252)
p value† 0.02 0.02
Lp(a) (mg/dl)
NA 14 (7–44) 10 (7–38) 9 (5–28)
Placebo 14 (7–53) 18 (6–49) 18 (6–49)
p value†‡ 0.04 0.003
apo B (g/l)
NA 0.82 0.17 0.70 0.13 0.73 0.14
Placebo 0.84 0.21 0.80 0.19 0.82 0.14
p value† 0.01 0.003
apo AI (g/l)
NA 1.27 0.16 1.29 0.20 1.32 0.17
Placebo 1.20 0.14 1.19 0.16 1.18 0.16
p value† 0.2 0.1
CRP (mg/l)
NA 12.9 (4.4–18.8) 12.1 (3.7–18.0) 5.7 (3.2–14.1)
Placebo 12.4 (3.8–3.2) 14.0 (4.6–27.5) 12.2 (5.1–23.8)
p value†‡ 0.03 0.1
Adiponectin (m/ml)
NA 10.0 6.8 18.5 15.0 19.4 16.8
Placebo 8.6 6.8 10.0 9.4 11.0 11.0
p value† 0.001 0.002
HbA1c (%)
NA 6.9 (6.2–8.2) 7.0 (6.0–8.2) 6.7 (6.0–8.5)
Placebo 7.4 (6.8–8.0) 6.5 (6.0–8.0) 6.9 (6.0–8.2)
p value†‡ 0.02 0.07
Summary statistics reported as mean SD or median (interquartile range); †p values derived
rommixed-effect model on outcomes defined as change from 6 (or 12 months) from baseline, ad-
usting for baseline prognostic covariates; ‡analysis was carried out on log-transformed data.
apo  apolipoprotein; CRP  C-reactive protein; HbA1c  glycosylated hemoglobin; HDL-C 
igh-density lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol; Lp(a)  lipopro-
ein(a); NA  nicotinic acid; Total-C  total cholesterol.he unblinding of the data to the statistician.esults
total of 71 patients were randomized, mean age 65 years.
aseline characteristics were similar between groups (Table 1).
igure 1 illustrates the flow of participants through the
tudy. Seven patients randomized to NA withdrew from
he study citing side effects that were possibly attributable
o NA: gastrointestinal (n  3), skin flushing or itching
n  3), and hyperglycemia (n  1). Medication adher-
nce assessed by pill count in those who completed the
tudy was similar between NA (93%) and placebo (92%)
roups. Of the patients who completed the study, 2
atients in each group had carotid images of insufficient
uality for wall area analysis. All patients had adequate
mage quality for assessment of aortic and brachial
arameters.
Table 2 summarizes the data from blood samples. No
tatin dose alteration occurred during the study. In the
A-treated group, mean HDL-C increased by 23% and
DL-C was reduced by 19% at 12 months. Triglycerides,
polipoprotein B, and lipoprotein(a) were significantly de-
reased by NA compared with placebo. CRP was decreased
y NA compared with placebo (p  0.03 at 6 months, p 
.1 at 12 months). Adiponectin was significantly increased
t both 6 and at 12 months (p  0.01). From the safety
erspective, minor transient elevations were noted in crea-
ine kinase and liver enzymes, but no significant, sustained
levations (3 the upper limit of normal for 2 weeks)
ere observed in any subjects. Fasting glucose did not
hange significantly, but glycated hemoglobin showed a
Figure 2 Effects of NA Treatment on Change in Mean
Wall Area of the Carotid Arteries Quantified by MRI
Bars indicate mean (SD) combined change for the right and left carotid arteries
at 6 months (open bars) and 12 months (solid bars). Within group, the mean
change in carotid wall area at 12 months was 1.1  2.6 mm2 for nicotinic
acid (NA) and 1.2  3.0 mm2 for placebo. For the primary end point, the NA
group had significantly greater change in carotid wall area at 12 months com-
pared with placebo (adjusted treatment difference: 1.64 mm2 [95% confi-
dence interval: 3.12 to 0.16]; p  0.03). MRI  magnetic resonance
imaging.
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November 3, 2009:1787–94 MRI of Atherosclerosis Response to Nicotinic Acidmall increase in the NA group versus placebo (p  0.02 at
months, p 0.07 at 12 months). Blood pressure and body
ass index did not change significantly in either group.
For the primary end point, the NA group had signifi-
antly greater change in carotid wall area at 12 months,
ompared with placebo (adjusted treatment difference:
1.64 mm2 [95% confidence interval (CI): 3.12 to
0.16]; p  0.03). Within group, the mean change in
arotid wall area was 1.1  2.6 mm2 for NA and 1.2 
.0 mm2 for placebo (Fig. 2). Similarly, at 12 months
hange in carotid plaque index (wall area normalized to total
essel area) was also reduced by NA treatment (estimated
reatment difference 0.016 [95% CI: 0.03 to 0.0022];
 0.02). At the earlier time point of 6 months, change in
arotid plaque index was lower in the NA-treated group
treatment difference 0.016 [95% CI: 0.03 to 0.0019];
 0.03), although change in absolute carotid wall area did
ot reach statistical significance at that point (treatment
ifference 0.98 mm2 [95% CI: 2.45 to 0.49]; p  0.2).
epresentative images of carotid plaque at 0 and 12 months,
n each treatment group, are shown in Figure 3. We
xamined the relationship between baseline carotid wall area
nd change in wall area at 12 months. In both the treatment
nd placebo groups, larger plaques were more prone to
hanges in size (r  0.4, p  0.04 for placebo, and r 
0.5, p  0.02 for NA). Since NA treatment raised
DL-C and lowered LDL-C, we also show the relation-
hips between these lipid measures and change in carotid
all area (Fig. 4).
There was significant reduction in aortic wall area at 6
onths in the NA-treated group compared with placebo
estimated treatment difference 6.40 mm2 [95% CI:
12.27 to 0.54]; p  0.03). At 12 months, the estimated
Figure 3 Atheroma Regression and Progression
Magnetic resonance images of carotid arteries in cross section, obtained at
baseline and at 12 months, showing atheroma progression and regression in
placebo and nicotinic acid-treated patients.rreatment difference was 5.08 mm2 (95% CI: 12.83 to
.67; p  0.2). Neither aortic distensibility nor flow-
ediated dilation of the brachial artery was significantly
ffected by NA treatment (Table 3).
iscussion
he addition of high-dose NA (2 g daily) to statin treat-
ent reduced mean carotid artery wall area, within 12
onths, in patients with low HDL-C (40 g/dl) and
therosclerosis. This is the first demonstration of an incre-
ental effect of NA, added to statin treatment, when
ompared with placebo.
In the 1970s, the Coronary Drug Project demonstrated a
Figure 4 Change in Carotid Wall Area
Versus HDL-C and LDL-C
(A) Scatterplot of 12-month change in carotid wall area (CWA) versus 12-month
change in high-density lipoprotein cholesterol (HDL-C). (B) Scatterplot of
12-month change in CWA versus 12-month change in low-density lipoprotein
cholesterol (LDL-C). Open circles indicate placebo group and solid circles nico-
tinic acid-treated group.eduction in cardiovascular events with NA treatment at
i
H
o
e
(
s
c
h
l
k
(
E
N
i
t
g
o
s
m
i
c
t
t
e
H
i
(
c
o
M
f
b
i
v
s
a
i
c
n
s
i
r
H
p
i
6
a
m
a
f
d
b
s
r
h
N
w
b
a
d
s
s
e
e
t
d
L
p
w
s
i
M
S
f
j
1792 Lee et al. JACC Vol. 54, No. 19, 2009
MRI of Atherosclerosis Response to Nicotinic Acid November 3, 2009:1787–94nitial follow-up and in mortality after 15 years (19).
owever, statins have since become the pre-eminent class
f LDL-C–lowering drugs in secondary prevention, and the
ffects of NA in this context are unknown. The HATS
HDL-Atherosclerosis Treatment Study) trial demon-
trated a reduction in events and coronary atheroma for the
ombination of NA and simvastatin, but this study did not
ave a statin monotherapy group for comparison, and the
ow dosage of simvastatin (mean 13 mg/day) was not in
eeping with current practice (20). In the ARBITER 2
Arterial Biology for the Investigation of the Treatment
ffects of Reducing Cholesterol 2) study, treatment with
A 1 g daily was associated with no change in carotid
ntima-media thickness (IMT), while IMT progressed in
he placebo group over 1 year (21). The difference between
roups did not reach statistical significance. The follow-up
pen-label cross-over study, ARBITER 3, reported regres-
ion of carotid IMT after a further 12 months NA treat-
ent (22). By contrast, our current study of high-dose NA
RI DataTable 3 MRI Data
Baseline 6 Months 12 Months
Carotid wall area (mm2)
NA 35.3 9.5 34.5 8.6 34.2 8.5
Placebo 29.9 4.8 30.6 5.9 31.0 6.6
p value* 0.2 0.03
Aortic wall area (mm2)
NA 194.2 44.4 195.3 44.2* 197.3 43.6
Placebo 173.8 30.8 178.9 32.7 179.6 35.7
p value* 0.03 0.2
Ascending aorta distensibility
( 103 mm Hg1)
NA 1.6 (1.1–2.3) 1.7 (1.3–2.4) 1.8 (1.2–2.4)
Placebo 1.7 (0.9–2.8) 1.9 (0.9–3.3) 1.7 (1.1–2.3)
p value*† 0.5 0.8
Proximal descending aorta
distensibility
( 103 mm Hg1)
NA 2.4 (1.7–3.4) 2.6 (1.8–3.8) 2.6 (1.9–4.2)
Placebo 2.1 (1.2–3.2) 2.4 (1.3–3.7) 2.2 (1.3–3.7)
p value*† 0.3 0.5
Distal descending aorta distensibility
( 103 mm Hg1)
NA 3.5 (2.2–4.5) 3.5 (2.0–4.8) 4.2 (2.1–5.4)
Placebo 3.2 (1.7–5.3) 3.3 (2.3–5.2) 3.4 (1.8–6.3)
p value* 0.5 0.7
Brachial FMD response (%)
NA 5.3 3.3 8.5 5.8 9.3 5.2
Placebo 8.4 4.9 6.9 4.7 8.0 4.0
p value* 0.07 0.1
Brachial GTN response (%)
NA 34.2 20.0 27.7 16.0 28.8 17.6
Placebo 32.7 16.8 29.3 12.5 32.1 11.8
p value* 1.0 0.8
ummary statistics reported as mean  SD or median (interquartile range). *p values derived
rommixed-effect model on outcomes defined as change from 6 (or 12 months) from baseline, ad-
usting for baseline prognostic covariates; †analysis was carried out on log-transformed data.
FMD  flow-mediated dilation; GTN  glyceryl trinitrate; other abbreviations as in Table 1.n combination with statins reveals significant benefit of NA tompared with placebo, with atherosclerosis regression in
he treatment group. The additional benefit apparent in
he current study may have both biological and technical
xplanations.
First, in the current study, NA 2 g daily both raised
DL-C by 23% and also reduced LDL-C by 19%. This is
n line with previous reports of use of NA at the 2-g dose
23,24). Our data cannot establish with certainty the relative
ontributions of each of these potentially beneficial effects
n plasma lipoprotein profile. Second, assessment with
RI may bring enhanced sensitivity over other modalities
or the detection of relatively small changes in atheroma
urden. A particular advantage of MRI is the ability to
nterrogate multiple arteries noninvasively and to obtain
olumetric data. Measurements are less sensitive to inter-
tudy variability along the length and circumference of the
rtery and to spatially selective measurements that fail to
dentify the full extent of disease (25,26). As a result,
hanges in arterial wall can be detected in a relatively small
umbers of patients (11,27). Aortic wall area was also
ignificantly reduced at 6 months. The absence of a signif-
cant difference at 12 months, despite a persistent numeric
eduction, may reflect insufficient statistical power.
A likely mechanism for the benefit of NA observed is
DL-C elevation and enhanced reverse cholesterol trans-
ort (28). Further benefits might arise through anti-
nflammatory effects as reductions in CRP were observed at
months, or through elevation of the ‘atheroprotective’
dipokine adiponectin (29).
As well as measuring plaque burden, we used the multi-
odal capabilities of MRI to examine pre-specified second-
ry end points in: 1) flow-mediated vasodilation of the
orearm, a marker of endothelial function; and 2) aortic
istensibility. We observed a trend towards improvement in
rachial endothelial function with NA treatment in this
tudy (p  0.07 and p  0.1 after 6 and 12 months,
espectively). Some studies using ultrasound-based methods
ave reported improvement in endothelial function after
A treatment either as monotherapy or in combination
ith other lipid medication, although this finding has not
een universally confirmed (30–34). Assessment of brachial
rtery reactivity by MRI has been evaluated against and
emonstrated to be at least equivalent to established ultra-
ound methods (35,36).
Aortic stiffness is associated with the presence of athero-
clerosis and an independent predictor of cardiovascular
vents (37). We and others have demonstrated beneficial
ffects of statins on aortic stiffness in patients with hyper-
ension (38) and coronary artery disease (13). In this study,
espite effects of NA therapy on both HDL-C and
DL-C, there was no effect of NA on arterial stiffness. It is
ossible that vessels of patients in the current study, who
ere pre-selected for peripheral arterial disease, were less
usceptible to improvement or that the full extent of any
mprovement had been achieved by the pre-existing statin
herapy.
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November 3, 2009:1787–94 MRI of Atherosclerosis Response to Nicotinic AcidAs anticipated, some patients withdrew from the study
ue to drug side effects. However, at 7 of 35 (20%), the rate
f drop out in the NA group was similar to previous studies
f modified release NA at 2 g per day (8,39,40) and had
een allowed for in the sample size calculation. Although, in
ommon with all studies of this drug, flushing and other
ide effects of NA could potentially have affected patient and
nvestigator ‘blinding,’ all analysis was undertaken blind to
atient identity and time point.
Our study provides further evidence for a beneficial effect
rom addition of NA to statin therapy. Although in epide-
iological studies HDL-C is inversely related to cardiovas-
ular risk, a beneficial effect of therapeutic HDL-C eleva-
ion cannot be assumed. For example, treatment with the
holesteryl ester transfer protein inhibitor, torcetrapib,
aised HDL-C by 72% but resulted in excess total mortality
41). Treatment with torcetrapib was not associated with
eduction in carotid IMT assessed by ultrasound (42,43) or
oronary atheroma quantified by intravascular ultrasound
44). Had the results of these studies been available before
he clinical outcome studies, the dissociation between
lasma HDL-C and clinical events might have been antic-
pated. In the case of NA, 2 large outcome trials are
nderway. The AIM-HIGH (Atherothrombosis Interven-
ion in Metabolic Syndrome with Low HDL/High Trig-
ycerides and Impact on Global Health Outcomes) study
as projected completion in 2011, while the HPS2-
HRIVE (Heart Protection Study 2–Treatment of HDL
o Reduce the Incidence of Vascular Events) study, will
ssess a new combination therapy containing extended-
elease niacin and a specific blocker of prostaglandin D2 to
revent flushing (projected completion 2013). Our findings
hat HDL-C elevation with NA reduces carotid plaque
urther intensify interest in the outcome of these studies.
tudy limitations. In addition to measuring plaque size,
RI can also determine plaque composition (e.g., lipid-rich
ecrotic core). Underhill et al. (14) have recently demon-
trated regression of this plaque component over 24 months
n patients with pre-existing carotid plaques who were
reated with rosuvastatin. Data from experimental animal
odels suggest that high-density lipoprotein elevation can
avorably modify atherosclerotic plaque composition, reduc-
ng lipid content (45–47). Although magnetic resonance
nalysis of plaque lipid-rich cores was intended as a second-
ry end point, the prevalence of this feature in this study was
oo low to allow meaningful analysis. This study enrolled
ainly male and Caucasian patients, so applicability to
ther populations may be limited. It was not powered to
etect changes in clinical event rates. Mild disturbance in
lycemic control with NA observed here is well recognized
ith NA (9); the clinical significance will be determined by
arge ongoing outcome studies.
Secondary prevention in atherosclerosis with statin drugs
as proved a successful approach in multiple patient groups
ut prevents only a minority of events. Progressively higher
oses of statins are associated with diminishing clinicalenefits and increased side effects (48). Epidemiological and
xperimental observations recommend HDL-C elevation as
compelling additional target. Our study shows, for the first
ime, that in patients with low HDL-C and existing
therosclerotic disease, addition of NA 2 g daily to contem-
orary therapy reduces atherosclerosis compared with pla-
ebo. The findings support current recommendations for
he use of NA and strongly underpin the rationale for the
arge clinical outcome studies that are ongoing.
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